Egypt ATTR (Transthyretin Amyloidosis) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. An rare and progressive condition known as ATTR (Transthyretin Amyloidosis) is characterised by the buildup of aberrant proteins in the body, including misTTR. The market for treatments for transthyretin amyloidosis is primarily driven by the expansion of the population and the availability of favourable reimbursement programmes. The market is predicted to increase as a result of strategic actions done by major players such raising knowledge of the target conditions like ATTR and the long-term advantages of treatments that are currently accessible. The market for treating transthyretin amyloidosis is currently constrained by a number of factors, including low awareness of the condition in developing nations, misdiagnosis of the condition, high costs of disease diagnosis and treatment, the lack of adequate clinical trials, and the absence of effective medications. Pfizer Inc., Johnson & Johnson Services, Inc., Ionis Pharmaceuticals, Alnylam Pharmaceuticals, BridgeBio Pharma, Bristol-Myers Squibb Company, Acrotech Biopharma, AstraZeneca, Astellas Pharma, Inc., Prothena, SOM Biotech, and numerous others are global competitors in the ATTR (Transthyretin Amyloidosis) market.
Egypt ATTR (Transthyretin Amyloidosis) Therapeutics Market is valued at around $14.31 Mn in 2022 and is projected to reach $28.72 Mn by 2030, exhibiting a CAGR of 9.1% during the forecast period 2023-2030.
The body's organs and tissues are affected by this uncommon, progressive disease, which is characterised by the accumulation of aberrant proteins like mister. The disease's symptoms primarily relate to the organs affected, such as carpel syndrome in the arms, lumbar spinal stenosis in the back, vitreous opacities in the head and neck, and oedema in the feet. The two main forms of transthyretin amyloidosis are wild-type ATTR and mutated/hereditary ATTR. Major body organs like the liver, kidney, nerves, and heart are frequently impacted by it.
The Amyloidosis Foundation estimates that there are approximately 126 different genetic variations in ATTR and up to 53 types of genetic variations in hereditary amyloidosis illnesses that are not transthyretin-related. Transthyretin amyloidosis reports have indicated that approximately 10,000, or 1.1 per 100,000 people worldwide, are thought to have TTR-FAP. Patients with the disease typically fall within the 30- to 40-year-old age range. TTR-CM has also been seen to primarily affect older guys 65 years of age and older. The likelihood of a parent with the mutation passing it on to their offspring is only 50%. Tissue biopsies, genetic tests, and cardiac imaging examinations are used to make the diagnosis of transthyretin amyloidosis.
An increase in disease prevalence, an increase in the population of people with African ancestry, an increase in awareness, advancements in diagnostic techniques, enhancements in healthcare services, swift economic development in developing nations, and an increase in research and development activity are likely to drive the global transthyretin amyloidosis treatment market. Contrarily, low levels of awareness in poor nations, incorrect diagnoses of the disease, high costs of disease diagnosis and treatment, a dearth of clinical studies, and a lack of effective medications are the main obstacles holding back the market for transthyretin amyloidosis treatments.
Pfizer Inc., Johnson & Johnson Services, Inc., Ionis Pharmaceuticals, Alnylam Pharmaceuticals, BridgeBio Pharma, Bristol-Myers Squibb Company, Acrotech Biopharma, AstraZeneca, Astellas Pharma, Inc., Prothena, SOM Biotech, and many others are global competitors in the ATTR (Transthyretin Amyloidosis) market.
Market Drivers
The market for treatments for transthyretin amyloidosis is primarily driven by the existence of favourable reimbursement programmes and the expanding population. Transthyretin amyloidosis is predicted to have a higher survival rate and a better prognosis with greater research efforts aimed at creating novel diagnostic methods and multimodal therapy approaches. Industry growth is anticipated to be fueled by strategic measures done by major firms, such as raising awareness of the target conditions, such as ATTR, and the long-term advantages of available medicines. For instance, the "Heart Hero" campaign was launched by Pfizer, Inc. and the World Heart Federation in 2019. Pfizer, Inc. offers clinicians and patients resources and educational material about ATTR-CM as part of this programme. Such initiatives are anticipated to increase the early
Market Restraints
The expansion of the transthyretin amyloidosis therapy market is significantly hindered by the lack of sophisticated diagnostic facilities in underdeveloped nations. In addition, the market for ATTR (Transthyretin Amyloidosis) Therapeutics is being constrained by a lack of awareness in developing economies, disease misdiagnosis, high costs associated with disease diagnosis and treatment, a lack of clinical studies, and a lack of effective medications.
Key players
Pfizer Alnylam Pharmaceuticals Dicerna Pharmaceuticals Ionis Pharmaceuticals uniQure Prothena Biosciences Stealth Biotherapeutics Wave Life Sciences Voyager Therapeutics Alcobra1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By type
By treatment
By route of administration
By end users
Insights10 will provide you with the reports within 10 key parameters which are:
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses
Need more?